Recent advances in the search for novel 5-lipoxygenase inhibitors (Q28296738)

https://api.crossref.org/works/10.1111%2FBCPT.12114

Therapeutic options for 5-lipoxygenase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

The structure of human 5-lipoxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

Collagen-induced arthritis is reduced in 5-lipoxygenase-activating protein-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

2-ABT-S-oxide detoxification by glutathione S-transferases A1-1, M1-1 and P1-1: implications for toxicity associated with zileuton

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

The discovery of setileuton, a potent and selective 5-lipoxygenase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

MK-0633, a potent 5-lipoxygenase inhibitor, in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

Novel cytochrome P450-mediated ring opening of the 1,3,4-oxadiazole in setileuton, a 5-lipoxygenase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

Pharmacology of PF-4191834, a novel, selective non-redox 5-lipoxygenase inhibitor effective in inflammation and pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

In vitro-in vivo correlation and translation to the clinical outcome for CJ-13,610, a novel inhibitor of 5-lipoxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

The use of gastrointestinal intubation studies for controlled release development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

A medicinal extract of Scutellaria baicalensis and Acacia catechu acts as a dual inhibitor of cyclooxygenase and 5-lipoxygenase to reduce inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

Efficacy and safety of flavocoxid, a novel therapeutic, compared with naproxen: a randomized multicenter controlled trial in subjects with osteoarthritis of the knee.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

Acute liver injury due to flavocoxid (Limbrel), a medical food for osteoarthritis: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

Zileuton, a new efficient and safe systemic anti-acne drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

The regulation of human MMP-13 by licofelone, an inhibitor of cyclo-oxygenases and 5-lipoxygenase, in human osteoarthritic chondrocytes is mediated by the inhibition of the p38 MAP kinase signalling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

Licofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

Licofelone: the answer to unmet needs in osteoarthritis therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

Pharmacodynamics and pharmacokinetics of AM103, a novel inhibitor of 5-lipoxygenase-activating protein (FLAP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005 ((R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid) and structurally related compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

Potent inhibitors of 5-lipoxygenase identified using pseudoreceptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

Homology modeling of 5-lipoxygenase and hints for better inhibitor design

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

Pseudoreceptor models in drug design: bridging ligand- and receptor-based virtual screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

PhAST: pharmacophore alignment search tool

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

Bioactivity-guided mapping and navigation of chemical space.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

Dual-target virtual screening by pharmacophore elucidation and molecular shape filtering

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

A comparison of antiasthma drugs between acute and chronic ovalbumin-challenged guinea-pig models of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

Conversion of pro-inflammatory murine Alox5 into an anti-inflammatory 15S-lipoxygenating enzyme by multiple mutations of sequence determinants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114

Rationally designed multitarget agents against inflammation and pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12114